MADRID, JANUARY 31 (EUROPA PRESS) –
In Spain, more than 80% of the clinical oncology clinical sessions are promoted by the pharmaceutical sector, as mentioned in Farmaindustry, Wednesday, 4 February, on the occasion of the celebration of Cancer Against World Day.
In this area, "the pharmaceutical industry is fully committed to the collection, development and availability of antitumor drugs that are more and more precise, and in recent years the door has opened new immunotherapies and gene therapies and cell phones, the basis for new precision medicine."
"The latest progress also means establishing a new era of cancer approach, considering the illness, as well as being part of a variety of different pathologies due to its molecular and genetic profiles," they added.
Therefore, keep in mind that cancer continues to make great efforts in R & D in the pharmaceutical industry. That is, accepting 42 drugs totally approved by Europeans in 2018, a total of 11 (26%) are new treatments against different types of cancer. Among these, the main therapies between the two genes stand out against different variants. Disease, according to the latest European Medicines Agency (EMA).
In this regard, 84 (23%) of the 84 positive opinions on new diseases reported by EMA correspond to the treatment of different types of cancers. The positive comments of the EMA are: the decisions of the European Commission's decision, later on, the procedure.
Anti-tumor antibodies against the new active substance are aimed at the treatment of different tumors of the blood, as well as the treatment of lung, breast, prostate, bladder, ovaries, fallopian tubes and peritoneum cancer, and to treat melanoma and lymphoma variations.
EXCLUDICATION OF CLINICAL RESEARCH
Among the excellence projects of 2016 June 2016, the latest data in clinical research show that cancer is the most pathologically active in clinical research, almost 50% of all the pharmaceutical industry last year developed clinical trials in oncology.
This oncology effort has been growing. Thus, in the period 2004-2009, 31% of clinical trials promoted in the pharmaceutical industry accounted for 39.4% of 2010 and 2012, with 31% of clinical trials, and finally 49.6% for 2015-2018.
Cancer, confirmed by recent publications, is a growing challenge for modern society and is trying to do pharmaceutical industries. "All of these data emphasize the effort made by the Spanish-based pharmaceutical company to discover and develop new drugs that guarantee a great deal of cancer treatment," says Farmaindustria CEO Humberto Arnés.
In his opinion, although significant progress has been made in the last decades, "there is still a long way to get the best results, if all agents involved (public administrations, industry, health professionals, researchers and patients) to give new solutions to patients who are not yet ".